Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588686 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
A Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by Vicore Pharma AB.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06588686: Recruiting Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by Vicore Pharma AB.
NCT06588686 is a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) that is actively recruiting participants, run by Vicore Pharma AB. The registered enrollment target is 360 participants, below the 452-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06588686, a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), is actively recruiting participants, sponsored by Vicore Pharma AB.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Primary Outcome
• Absolute change from baseline in FVC (mL) at week 52
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Buloxibutid
Study Locations (20)
California
- Keck Medicine of University of Southern California - Los Angeles
- Paradigm Clinical Research Centers, Inc. - Redding
- UC Davis Health System - Sacramento
- UC San Diego Medical Center - Hillcrest - San Diego
- Paradigm Clinical Research - San Diego
Florida
- University of Florida Health (UF Health) - Gainesville
- Clinical Research Specialists - Kissimmee
Alabama
- UAB Hospital, School of Medicine/Lung Health Center - Birmingham
Colorado
- National Jewish Medical and Research Center - Denver
Georgia
- Emory Saint Joseph's Hospital - Atlanta
Illinois
- Endeavor Health - Evanston Hospital - Evanston
Kansas
- University of Kansas Medical Center - Kansas City
Massachusetts
- Massachusetts General Hospital, Pulmonary & Critical Care Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT06588686 shows while recruiting
NCT06588686 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 452-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06588686 names 20 study sites across 15 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06588686 about?
NCT06588686 is a clinical study titled "A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.". The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial w...
What is the current status of trial NCT06588686?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2024-12-09. Estimated completion is 2027-06.
What conditions does trial NCT06588686 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF).
What interventions are being tested in trial NCT06588686?
The interventions under investigation include: Placebo (DRUG), Buloxibutid (DRUG).
Who is sponsoring clinical trial NCT06588686?
This trial is sponsored by Vicore Pharma AB, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588686 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis (IPF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06588686's enrollment target sits among peer trials
360 3rd of 8 higher than 6 of 8 other Idiopathic Pulmonary Fibrosis (IPF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis (IPF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RECRUITING · Phase 2
-
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
COMPLETED · Phase 2
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
The Genetics of Pulmonary Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI